Patents by Inventor Tsiona Elkayam

Tsiona Elkayam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Alginate biomaterials for the treatment of hepatic disorders
    Patent number: 10328098
    Abstract: The present invention relates to methods for the treatment of hepatic disorders in a subject in need thereof. More specifically, the methods of the invention are based on the administration, preferably, systemic administration, of a therapeutically effective amount of at least one biocompatible alginate biomaterial, any modification thereof and any combination thereof. The invention further provides methods for sustaining serum albumin levels, and/or reducing serum AST and ALT, in subjects suffering from hepatic disorder. Still further, the invention provides methods for reducing apoptosis and inducing cell proliferation in a damaged liver tissue of a subject suffering of hepatic disorder, using the alginate biomaterial described by the invention.
    Type: Grant
    Filed: July 10, 2016
    Date of Patent: June 25, 2019
    Assignees: Hadasit Medical Research Services and Development Ltd., Ben-Gurion University of the Negev Research and Development Authority
    Inventors: Yaron Ilan, Gadi Lalazar, Eyal Shteyer, Ami Ben-Ya'acov, Smadar Cohen, Tsiona Elkayam
  • ALGINATE BIOMATERIALS FOR THE TREATMENT OF HEPATIC DISORDERS
    Publication number: 20160317570
    Abstract: The present invention relates to methods for the treatment of hepatic disorders in a subject in need thereof. More specifically, the methods of the invention are based on the administration, preferably, systemic administration, of a therapeutically effective amount of at least one biocompatible alginate biomaterial, any modification thereof and any combination thereof. The invention further provides methods for sustaining serum albumin levels, and/or reducing serum AST and ALT, in subjects suffering from hepatic disorder. Still further, the invention provides methods for reducing apoptosis and inducing cell proliferation in a damaged liver tissue of a subject suffering of hepatic disorder, using the alginate biomaterial described by the invention.
    Type: Application
    Filed: July 10, 2016
    Publication date: November 3, 2016
    Applicants: Hadasit Medical Research Services and Development Ltd., Ben-Gurion University of the Negev Research and Development Authority
    Inventors: Yaron ILAN, Gadi LALAZAR, Eyal SHTEYER, Ami BEN-YA'ACOV, Smadar COHEN, Tsiona ELKAYAM
  • Alginate biomaterials for the treatment of hepatic disorders
    Patent number: 9387222
    Abstract: The present invention relates to methods for the treatment of hepatic disorders in a subject in need thereof. More specifically, the methods of the invention are based on the administration, preferably, systemic administration, of a therapeutically effective amount of at least one biocompatible alginate biomaterial, any modification thereof and any combination thereof. The invention further provides methods for sustaining serum albumin levels, and/or reducing serum AST and ALT, in subjects suffering from hepatic disorder. Still further, the invention provides methods for reducing apoptosis and inducing cell proliferation in a damaged liver tissue of a subject suffering of hepatic disorder, using the alginate biomaterial described by the invention.
    Type: Grant
    Filed: November 27, 2008
    Date of Patent: July 12, 2016
    Assignees: Hadasit Medical Research Services and Development Ltd., Ben-Gurion University of the Negev Research and Development Authority
    Inventors: Yaron Ilan, Gadi Lalazar, Eyal Shteyer, Ami Ben-Yaakov, Smadar Cohen, Tsiona Elkayam
  • Alginate Biomaterials for the Treatment of Hepatic Disorders
    Publication number: 20100247652
    Abstract: The present invention relates to methods for the treatment of hepatic disorders in a subject in need thereof. More specifically, the methods of the invention are based on the administration, preferably, systemic administration, of a therapeutically effective amount of at least one biocompatible alginate biomaterial, any modification thereof and any combination thereof. The invention further provides methods for sustaining serum albumin levels, and/or reducing serum AST and ALT, in subjects suffering from hepatic disorder. Still further, the invention provides methods for reducing apoptosis and inducing cell proliferation in a damaged liver tissue of a subject suffering of hepatic disorder, using the alginate biomaterial described by the invention.
    Type: Application
    Filed: November 27, 2008
    Publication date: September 30, 2010
    Applicants: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD., BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY
    Inventors: Yaron Ilan, Gadi Lalazar, Eyal Shteyer, Ami Ben-Yaakov, Smadar Cohen, Tsiona Elkayam